A Phase 1/2 interventional study of golidocitinib in Relapsed or Refractory Peripheral T Cell Lymphoma, sponsored by Dizal Pharmaceuticals. Completed at 50 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by Dizal Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral — 13 open to participants now, 13 under way, 3 of them phase 3. golidocitinib · Lymphoma, T-Cell, Peripheral.
Among the 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral, this one is the 2nd largest by enrollment, is the only one that started in 2019, is one of 6 in phase 1/2, and was the 1st registered.
372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.
Browse Lymphoma, T-Cell, Peripheral studies →13 of the 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral are open now, in 4 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 13 · Phase 3 3
First in 2019; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 171 is above the median of 44 across 328 interventional studies indexed under Lymphoma, T-Cell, Peripheral.
Median enrollment 53 across the 16 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 16 have an industry lead sponsor. The 9 most frequent:
Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.
Dizal Pharmaceuticals has 4 studies filed under Lymphoma, T-Cell, Peripheral — fewer than ten, so there is no comparison to draw.
4 of the studies testing golidocitinib in Lymphoma, T-Cell, Peripheral that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07234162Phase 3Dizal PharmaceuticalsA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) | 2027-11-30 |
| NCT07279584Ruijin HospitalGolidocitinib Combined With GemOx in RR PTCL | 2026-12-31 |
| NCT06630091M.D. Anderson Cancer CenterA Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study | 2027-07-05 |
| NCT07093710Sun Yat-sen UniversityGolidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma | 2027-08-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing golidocitinib in Lymphoma, T-Cell, Peripheral, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to standard systemic treatment.
Phase 1 part:
Around 20\~40 patients will be subsequently enrolled into 2 different dose ascending cohorts. Additional 10\~20 patients may be enrolled to further explore a selected dose defined by dose escalation cohorts.
Phase 2 part:
After the recommended phase 2 dose (RP2D) is defined, a phase 2 single-arm open-label pivotal study will be conducted to assess anti-tumor efficacy and safety of AZD4205 at RP2D in patients with refractory or relapsed PTCL.
372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.
This study's enrollment of 171 is above the median of 44 across 328 interventional studies indexed under Lymphoma, T-Cell, Peripheral.
Browse Lymphoma, T-Cell, Peripheral studies →Dizal Pharmaceuticals is the lead sponsor of 39 studies on the registry; 15 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.
Compared within Lymphoma, T-Cell, Peripheral, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A: Open label golidocitinib at dose A, once daily (Phase 1)
Drug: golidocitinib
Group B: Open label golidocitinib at dose B, once daily (Phase 1)
Drug: golidocitinib
Group C: Open label golidocitinib at a selected dose, once daily (Phase 1)
Drug: golidocitinib
Group D: Open label golidocitinib at the RP2D, once daily (Phase 2)
Drug: golidocitinib
golidocitinib will be administered orally as capsules. golidocitinib treatment will be continued until disease progression or intolerant adverse reactions
Also known as: AZD4205
Part B: CT-based Objective Response Rate (ORR) by Independent Review Committee (IRC)
ORR is the percentage of patients with at least one visit response of Complete Response (CR) or Partial Response (PR) based on CT scans evaluated by IRC per Lugano criteria.
Time frame: Up to approximately 3 years
Part A and Part B: Number of Participants With Adverse Events
To evaluate the safety and tolerability of AZD4205 in patients with PTCL in terms of adverse events (AEs), such as number of participants with AEs
Time frame: The first dose until 28 days after last dose, up to approximately 3 years
Part B: Duration of Response (DoR) Assessed by IRC
DoR is the time from the date of first documented response until the date of documented progression or death due to any cause. Documented response and progression are both identified based on CT scans evaluated by IRC per Lugano criteria.
Time frame: Up to approximately 3 years
Part B: Complete Response Rate (CRR) Assessed by IRC
CRR is the percentage of patients with at least one visit response of CR based on CT scans evaluated by IRC per Lugano criteria.
Time frame: Up to approximately 3 years
Part B: Progression Free Survival (PFS) Assessed by IRC
PFS is the time from the date of first dosing until the date of objective disease progression or death (by any cause) regardless of whether the participant discontinues the study treatments. Progression is identified based on CT scans evaluated by IRC per Lugano criteria.
Time frame: Up to approximately 3 years
Part B: Time to Response (TTR) Assessed by IRC
TTR is the time from the date of first dosing to the time of the initial response of PR or CR. Response is identified based on CT scans evaluated by IRC per Lugano criteria.
Time frame: Up to approximately 3 years
Part A and Part B: ORR Assessed by Investigator
ORR is the percentage of patients with at least one visit response of CR or PR based on CT and/or PET scans evaluated by investigator per Lugano criteria.
Time frame: Up to approximately 3 years
Part A and Part B: DoR Assessed by Investigator
DoR is the time from the date of first documented response until the date of documented progression or death due to any cause. Documented response and progression are both identified based on CT and/or PET scans evaluated by investigator per Lugano criteria.
Time frame: Up to approximately 3 years
Part A and Part B: CRR Assessed by Investigator
CRR is the percentage of patients with at least one visit response of CR based on CT and/or PET scans evaluated by investigator per Lugano criteria.
Time frame: Up to approximately 3 years
Part A and Part B: PFS Assessed by Investigator
PFS is the time from the date of first dosing until the date of objective disease progression or death (by any cause) regardless of whether the participant discontinues the study treatments. Progression is identified based on CT and/or PET scans evaluated by investigator per Lugano criteria.
Time frame: Up to approximately 3 years
Part B: TTR Assessed by Investigator
TTR is the time from the date of first dosing to the time of the initial response of PR or CR. Response is identified based on CT scans evaluated by investigator per Lugano criteria.
Time frame: Up to approximately 3 years
Part A and Part B: Maximum Plasma Concentration (Cmax) of AZD4205
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose.
Time frame: Cycle 1 Day 1 (each cycle = 21 days): 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose (for Group A, B and C); 0 (predose), 1, 2, 4, 6, 8, and 24 hours postdose (for Group D).
Part A and Part B: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of AZD4205
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.
Time frame: Cycle 1, Day 1 (each cycle = 21 days): 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose (for Group A, B and C); 0 (predose), 1, 2, 4, 6, 8, and 24 hours postdose (for Group D).
Part A and Part B: Cmax,ss, at Steady State of AZD4205
Maximum observed plasma concentration (ng/mL) at steady state, obtained directly from the observed concentration versus time data. Calculated for the multiple doses.
Time frame: Cycle 2 Day 1 (each cycle = 21 days): 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose (for Group A, B and C); 0 (predose), 1, 2, 4, 6, 8, and 24 hours postdose (for Group D).
Part A and Part B: AUCss, at Steady State of AZD4205
Area under the plasma concentration-time curve from time zero to the last quantifiable time point at steady state, calculated by the linear up/log down rule
Time frame: Cycle 2 Day 1 (each cycle = 21 days): 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 hours postdose (for Group A, B and C); 0 (predose), 1, 2, 4, 6, 8, and 24 hours postdose (for Group D).
DZ2019J0005 study includes 2 parts: Part A, the dose escalation and extension part (group A, B, C), and part B, dose expansion part (group D). 51 and 120 participants were recruited in Part A and Part B respectively, based on physician referral at 31 sites in the U.S., Australia, China and South Korea. The first participant was enrolled on 10-Sep-2019 and the last participant was enrolled on 23-Aug-2023.
| Milestone | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Started | 28 | 16 | 7 | 120 |
| Completed | 13 | 7 | 5 | 39 |
| Not completed | 15 | 9 | 2 | 81 |
| Withdrew: Death | 3 | 1 | 1 | 54 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 4 |
| Withdrew: Withdrawal by subject | 8 | 1 | 1 | 4 |
| Withdrew: Other reason | 4 | 7 | 0 | 19 |
ORR is the percentage of patients with at least one visit response of Complete Response (CR) or Partial Response (PR) based on CT scans evaluated by IRC per Lugano criteria.
| percentage of participants | AZD4205 Group D |
|---|---|
| Part B: CT-based Objective Response Rate (ORR) by Independent Review Committee (IRC) | 43.1 (33.4 to 53.3) |
To evaluate the safety and tolerability of AZD4205 in patients with PTCL in terms of adverse events (AEs), such as number of participants with AEs
| Participants | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Part A and Part B: Number of Participants With Adverse Events | 26 | 16 | 6 | 115 |
DoR is the time from the date of first documented response until the date of documented progression or death due to any cause. Documented response and progression are both identified based on CT scans evaluated by IRC per Lugano criteria.
| months | AZD4205 Group D |
|---|---|
| Part B: Duration of Response (DoR) Assessed by IRC | NA (16.6 to NA) |
CRR is the percentage of patients with at least one visit response of CR based on CT scans evaluated by IRC per Lugano criteria.
| percentage of participants | AZD4205 Group D |
|---|---|
| Part B: Complete Response Rate (CRR) Assessed by IRC | 21.6 (14.0 to 30.8) |
PFS is the time from the date of first dosing until the date of objective disease progression or death (by any cause) regardless of whether the participant discontinues the study treatments. Progression is identified based on CT scans evaluated by IRC per Lugano criteria.
| months | AZD4205 Group D |
|---|---|
| Part B: Progression Free Survival (PFS) Assessed by IRC | 5.5 (3.0 to 18.7) |
TTR is the time from the date of first dosing to the time of the initial response of PR or CR. Response is identified based on CT scans evaluated by IRC per Lugano criteria.
| months | AZD4205 Group D |
|---|---|
| Part B: Time to Response (TTR) Assessed by IRC | 1.4 (1.4 to 1.5) |
ORR is the percentage of patients with at least one visit response of CR or PR based on CT and/or PET scans evaluated by investigator per Lugano criteria.
| percentage of participants | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Part A and Part B: ORR Assessed by Investigator | 46.4 (27.5 to 66.1) | 37.5 (15.2 to 64.6) | 14.3 (0.4 to 57.9) | 38.2 (28.8 to 48.4) |
DoR is the time from the date of first documented response until the date of documented progression or death due to any cause. Documented response and progression are both identified based on CT and/or PET scans evaluated by investigator per Lugano criteria.
| months | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Part A and Part B: DoR Assessed by Investigator | 5.09 (2.04 to NA) | NA (2.07 to NA) | 3.19 (NA to NA) | NA (4.4 to NA) |
CRR is the percentage of patients with at least one visit response of CR based on CT and/or PET scans evaluated by investigator per Lugano criteria.
| percentage of participants | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Part A and Part B: CRR Assessed by Investigator | 28.6 (13.2 to 48.7) | 12.5 (1.6 to 38.3) | 14.3 (0.4 to 57.9) | 14.7 (8.5 to 23.1) |
PFS is the time from the date of first dosing until the date of objective disease progression or death (by any cause) regardless of whether the participant discontinues the study treatments. Progression is identified based on CT and/or PET scans evaluated by investigator per Lugano criteria.
| months | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Part A and Part B: PFS Assessed by Investigator | 3.29 (1.31 to 3.58) | 2.50 (1.41 to NA) | 3.32 (1.41 to 5.26) | 3.4 (1.7 to 5.6) |
TTR is the time from the date of first dosing to the time of the initial response of PR or CR. Response is identified based on CT scans evaluated by investigator per Lugano criteria.
| months | AZD4205 Group D |
|---|---|
| Part B: TTR Assessed by Investigator | 1.4 (1.4 to 1.5) |
Maximum observed plasma concentration, obtained directly from the observed concentration versus time data. Calculated for the single dose.
| ng/mL | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Part A and Part B: Maximum Plasma Concentration (Cmax) of AZD4205 | 279.8 ± 29.2 | 512.0 ± 27.7 | 258.8 ± 36.9 | 229.2 ± 40.91 |
Area under the plasma concentration-time curve from time zero to the last quantifiable time point, calculated by the linear up/log down rule.
| h*ng/mL | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Part A and Part B: Area Under the Plasma Concentration-time Curve From Zero to the Last Measurable Concentration (AUC0-t) of AZD4205 | 3592 ± 26.0 | 6755 ± 25.0 | 3276 ± 21.1 | 3271 ± 35.24 |
Maximum observed plasma concentration (ng/mL) at steady state, obtained directly from the observed concentration versus time data. Calculated for the multiple doses.
| ng/mL | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Part A and Part B: Cmax,ss, at Steady State of AZD4205 | 673.5 ± 28.9 | 1152 ± 30.6 | 665.9 ± 27.4 | 539.0 ± 35.92 |
Area under the plasma concentration-time curve from time zero to the last quantifiable time point at steady state, calculated by the linear up/log down rule
| h*ng/mL | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Part A and Part B: AUCss, at Steady State of AZD4205 | 11978 ± 27.1 | 20991 ± 33.5 | 11822 ± 29.2 | 10000 ± 36.85 |
Collected over The first dose until 28 days after last dose, up to approximately 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD4205 Group A | 3/28 (10.7%) | 12/28 (42.9%) | 26/28 (92.9%) |
| AZD4205 Group B | 2/16 (12.5%) | 9/16 (56.3%) | 16/16 (100%) |
| AZD4205 Group C | 1/7 (14.3%) | 1/7 (14.3%) | 6/7 (85.7%) |
| AZD4205 Group D | 54/120 (45%) | 44/120 (36.7%) | 114/120 (95%) |
| Event | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 2/28 | 3/16 | 0/7 | 6/120 |
| COVID-19 pneumoniaInfections and infestations | 0/28 | 0/16 | 1/7 | 2/120 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/28 | 0/16 | 1/7 | 0/120 |
| PyrexiaGeneral disorders | 2/28 | 0/16 | 0/7 | 3/120 |
| Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders | 2/28 | 0/16 | 0/7 | 1/120 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 2/28 | 1/16 | 0/7 | 0/120 |
| Platelet count decreasedInvestigations | 1/28 | 1/16 | 0/7 | 3/120 |
| HypopituitarismEndocrine disorders | 0/28 | 1/16 | 0/7 | 0/120 |
| Small intestinal perforationGastrointestinal disorders | 0/28 | 1/16 | 0/7 | 0/120 |
| Drug-induced liver injuryHepatobiliary disorders | 1/28 | 1/16 | 0/7 | 0/120 |
| Event | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D |
|---|---|---|---|---|
| Platelet count decreasedInvestigations | 9/28 | 7/16 | 0/7 | 71/120 |
| Neutrophil count decreasedInvestigations | 6/28 | 7/16 | 1/7 | 62/120 |
| White blood cell count decreasedInvestigations | 6/28 | 4/16 | 1/7 | 62/120 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/28 | 2/16 | 3/7 | 0/120 |
| neutropeniaBlood and lymphatic system disorders | 6/28 | 2/16 | 3/7 | 6/120 |
| AnaemiaBlood and lymphatic system disorders | 7/28 | 4/16 | 2/7 | 51/120 |
| PyrexiaGeneral disorders | 9/28 | 6/16 | 1/7 | 24/120 |
| Lymphocyte count decreasedInvestigations | 5/28 | 0/16 | 0/7 | 36/120 |
| Blood fibrinogen decreasedInvestigations | 1/28 | 2/16 | 2/7 | 17/120 |
| Aspartate aminotransferase increasedInvestigations | 6/28 | 4/16 | 1/7 | 33/120 |
Safety Analysis Set (all patients treated with at least one dose of AZD4205)
| Age, Continuous(years) | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D | Total |
|---|---|---|---|---|---|
| Median | 62.5 (33 to 78) | 61.5 (29 to 79) | 55.0 (39 to 74) | 58.0 (20 to 79) | 58.0 (20 to 79) |
| Sex: Female, Male(Participants) | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D | Total |
|---|---|---|---|---|---|
| Female | 11 | 3 | 3 | 44 | 61 |
| Male | 17 | 13 | 4 | 76 | 110 |
| Race (NIH/OMB)(Participants) | AZD4205 Group A | AZD4205 Group B | AZD4205 Group C | AZD4205 Group D | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 28 | 16 | 7 | 100 | 151 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 4 | 4 |
| White | 0 | 0 | 0 | 14 | 14 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Oct 2023, 49 months.
Results were first posted in Apr 2025, 1 year 5 months after primary completion.
Of 31 phase 1/2 interventional studies under Lymphoma, T-Cell, Peripheral, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 65. This study's 49 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Golidocitinib
Lymphoma, T-Cell, Peripheral →